ArticleJournal of the American Heart Association2026
Cardiovascular Health Across Gender Identities: Life's Essential 8 in the PRIDE Study.
Article in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOur objective was to assess the cardiovascular health of sexual and gender minority adults across the sex and gender spectrum.
methodsThis was a cross-sectional analysis of the American Heart Association Life's Essential 8 (LE8) score in sexual and gender minority adults in The PRIDE (Population Research in Identity and Disparities for Equality) Study. Using a validated algorithm, self-reported gender identity was categorized: cisgender men, cisgender women, gender-expansive people assigned female at birth, gender-expansive people assigned male at birth, transgender men, and transgender women. We used linear regression to calculate the mean composite LE8 score (primary outcome) and mean LE8 component scores (secondary outcome) across groups.
resultsAmong the 4964 participants, the median age was 36.4 (interquartile range, 28.9-51.9) years, 49.7% (n=2398) were transgender or gender-expansive, and 1100 (22.2%) respondents used gender-affirming hormone therapy. Composite LE8 scores ranged from 70.3 (95% CI, 68.5-72.1) in transgender women to 72.9 (95% CI, 72.3-73.6) in gender-expansive people assigned female at birth, with no difference by gender-affirming hormone therapy use. Mean LE8 component scores differed significantly between groups, including a high prevalence of unfavorable body mass index scores in cisgender women and gender-expansive people assigned female at birth, unfavorable nicotine scores in gender-expansive people assigned male at birth and transgender men, and unfavorable sleep scores in transgender men and transgender women. Overall, participants had favorable physical activity and glucose scores and unfavorable diet scores.
conclusionsIn this sample of sexual and gender minority adults, the significant differences in the prevalence of unfavorable LE8 component scores between groups highlight the importance of population-specific interventions in future research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.